cas 35251-84-4|| where to buy Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

Produktname:Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

IUPAC Name:1H,2H,3H,4H-pyrido[3,4-b]pyrazine-2,3-dione

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM214023-1g	in stock	ƛƥ
CM214023-5g	1-2 Weeks	ŞȖȖ
CM214023-25g	1-2 Weeks	ƿƥŪ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 35251-84-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:35251-84-4; Molekulare Formel:C7H5N3O2; Schmelzpunkt:-; SMILES-Code:O=C1NC=2C=NC=CC2NC1=O; Dichte:

: Katalognummer:CM214023; Molekulargewicht:163.14; Siedepunkt:; Mdl-Nr.:MFCD01411816; Lagerung:

: Quinazolines; Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

: CVN424; In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.